Progress in HPV vaccination in low‐ and lower‐middle‐income countries
Open Access
- 9 July 2017
- journal article
- research article
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 138 (S1) , 7-14
Abstract
The past 10 years have seen remarkable progress in the global scale‐up of human papillomavirus (HPV) vaccinations. Forty‐three low‐ and lower‐middle‐income countries (LLMICs) have gained experience in delivering this vaccine to young adolescent girls through pilot programs, demonstration programs, and national introductions and most of these have occurred in the last 4 years. The experience of Senegal is summarized as an illustrative country case study. Publication of numerous delivery experiences and lessons learned has demonstrated the acceptability and feasibility of HPV vaccinations in LLMICs. Four areas require dedicated action to overcome remaining challenges to national scaling‐up: maintaining momentum politically, planning successfully, securing financing, and fostering sustainability. Advances in policy, programming, and science may help accelerate reaching 30 million girls in LLMICs with HPV vaccine by 2020.Keywords
This publication has 52 references indexed in Scilit:
- Costs of delivering human papillomavirus vaccination to schoolgirls in Mwanza Region, TanzaniaBMC Medicine, 2012
- A case study using the United Republic of Tanzania: costing nationwide HPV vaccine delivery using the WHO Cervical Cancer Prevention and Control Costing ToolBMC Medicine, 2012
- Human Papillomavirus Vaccine Introduction – The First Five YearsVaccine, 2012
- Acceptance patterns and decision-making for human papillomavirus vaccination among parents in Vietnam: an in-depth qualitative study post-vaccinationBMC Public Health, 2012
- Assessment of eight HPV vaccination programs implemented in lowest income countriesBMC Public Health, 2012
- Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trialThe Lancet Oncology, 2012
- Efficacy and Safety of Prophylactic Vaccines against Cervical HPV Infection and Diseases among Women: A Systematic Review & Meta-AnalysisBMC Infectious Diseases, 2011
- HPV - immune response to infection and vaccinationInfectious Agents and Cancer, 2010
- Intellectual property, technology transfer and manufacture of low-cost HPV vaccines in IndiaNature Biotechnology, 2010
- Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countriesVaccine, 2008